Safety and Efficacy of Transient Opening of the Blood-brain Barrier (BBB) With the SonoCloud-9 (SC9-GBM-01)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03744026 |
Recruitment Status :
Completed
First Posted : November 16, 2018
Last Update Posted : September 7, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Recurrent glioblastoma (GBM) is a disease with high unmet clinical need. The standard of care for patients with GBM includes surgery, radiotherapy and chemotherapy. Despite this aggressive treatment, the overall median survival of patients with GBM remains at 15-20 months.
In more than 95% of cases, tumor recurrence is observed within 2 cm to 3 cm of the resection cavity within 4-7 months after initial treatments. One of the main causes of recurrence is the inability of chemotherapies to enter the brain from the systemic circulation due to the blood-brain barrier (BBB). The BBB is unique to cerebral blood vessels and blocks most drugs from entering the brain in sufficient concentrations.
The SonoCloud-9 (SC9) System delivers ultrasound to locally and transiently increase the permeability of the BBB to allow the passage of drugs into the cerebral parenchyma. The SC9 is dimensioned to cover the resection area and surrounding tissues in patients with recurrent GBM. The large sonicated volume covered by the SC9 device allows for broad BBB disruption and should allow for carboplatin chemotherapy to penetrate the surrounding tumor infiltrative area. By enhancing drug concentrations, it is hypothesized that further disease progression will be prevented.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Glioblastoma, Adult | Device: SonoCloud-9 Drug: Carboplatin | Phase 1 Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 38 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Study to Evaluate the Safety and the Efficacy of Transient Opening of the Blood-brain Barrier (BBB) by Low Intensity Pulsed Ultrasound With the SonoCloud-9 Implantable Device in Recurrent Glioblastoma Patients Eligible for Surgery and for Carboplatin Chemotherapy |
Actual Study Start Date : | February 18, 2019 |
Actual Primary Completion Date : | June 23, 2021 |
Actual Study Completion Date : | June 30, 2022 |

Arm | Intervention/treatment |
---|---|
Experimental: SonoCloud-9 Ultrasound + Carboplatin
SonoCloud-9 Carboplatin: 6 cycles (every 4 weeks)
|
Device: SonoCloud-9
Escalating numbers of ultrasound beams at constant acoustic pressure Drug: Carboplatin Dose of carboplatin infusion is AUC4-6 |
- Dose limiting toxicity (DLT) of number of activated ultrasound beams [ Time Frame: 15 days after the first sonication treatment ]DLT will be evaluated using imaging (MRI) and clinical examination, as CTCAE that occurs within 2 weeks of the first sonication and that does not respond to optimal medical management (including steroids) within 7 days.
- Blood-Brain Barrier (BBB) opening [ Time Frame: At the end of the first three sonication treatments (treatment occurs every 4 weeks) ]BBB opening will be evaluated by contrast-enhanced T1w magnetic resonance imaging (MRI)

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Key Inclusion Criteria:
- Age ≥ 18 years, able and willing to give signed and informed consent.
-
Patient with histologically proven recurrent de novo GBM:
- After at least a first-line standard of care (maximal safe resection, if feasible, radiation with temozolomide [TMZ], then TMZ);
- Any recurrence;
- Bevacizumab-naïve.*
- Patient eligible for carboplatin-based chemotherapy.
- Patient eligible for a surgical resection.
- Maximal tumor diameter at inclusion (pre surgery) ≤ 70 mm in T1wMRI.
- Patients should be stable, without evidence of a midline shift, significant peritumoral edema, or rapid progression of clinical symptoms.
- Karnofsky performance status ≥ 70.
- Patient receiving prednisone dose ≤ 40 mg (dexamethasone ≤ 6 mg) for at least 7 days.
Key Exclusion Criteria:
- Multifocal tumor (unless all localized in a 70 mm diameter area).
- Patients at risk of surgery site infection (2 or more previous craniotomies, neurosurgery within the last 3 months, poor skin condition, and/or previously infected surgical field).
- Posterior fossa tumor.
- Uncontrolled epilepsy.
- Patients with evidence of uncontrolled intracranial pressure.
- Patients with known intracranial aneurism or having presented intra-tumor spontaneous hemorrhage.
- Patients with coils, clips, shunts, intravascular stents, and/or unremovable wafer, non resorbable dura substitute, or reservoirs.
- Patients with medical need to continue antiplatelet therapy.
- Patients with known or suspected active or chronic infections.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03744026
United States, Illinois | |
Northwestern University | |
Chicago, Illinois, United States, 60611 | |
United States, Texas | |
MD Anderson Cancer Center | |
Houston, Texas, United States, 77030 | |
France | |
CHU | |
Angers, France | |
Hôpital Neurologique Pierre Wertheimer | |
Bron, France | |
Hôpital de La Timone | |
Marseille, France | |
Hôpital de la Pitié-Salpêtrière | |
Paris, France |
Principal Investigator: | Ahmed IDBAIH, MD | APHP |
Publications:
Responsible Party: | CarThera |
ClinicalTrials.gov Identifier: | NCT03744026 |
Other Study ID Numbers: |
SC9-GBM-01 |
First Posted: | November 16, 2018 Key Record Dates |
Last Update Posted: | September 7, 2022 |
Last Verified: | September 2022 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Product Manufactured in and Exported from the U.S.: | No |
Recurrent Glioblastoma Carboplatin Ultrasound Blood-brain barrier |
Glioblastoma SonoCloud Low Intensity Pulsed Ultrasound (LIPU) |
Glioblastoma Astrocytoma Glioma Neoplasms, Neuroepithelial Neuroectodermal Tumors Neoplasms, Germ Cell and Embryonal |
Neoplasms by Histologic Type Neoplasms Neoplasms, Glandular and Epithelial Neoplasms, Nerve Tissue Carboplatin Antineoplastic Agents |